Aurobindo Pharma, today received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ramipril Capsules.
“Ramipril Capsules are indicated for the treatment of hypertension and falls under the Cardiovascular (CVS) therapeutic segment. The product has a market size of approximately $95 million for the twelve months ending September 2010 according to IMS and will be launched soon,” the company said in a release.
Hyderabad-based, Aurobindo Pharma now has a total of 138 ANDA approvals (108 final approvals and 30 tentative approvals) from USFDA.
Aurobindo Pharma Limited manufactures generic pharmaceuticals and active pharmaceutical ingredients.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app